Alexander Kretschmer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5511698/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. European Urology, 2016, 70, 553-557.	1.9	248
2	Biomarkers in prostate cancer – Current clinical utility and future perspectives. Critical Reviews in Oncology/Hematology, 2017, 120, 180-193.	4.4	135
3	Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. European Urology, 2019, 76, 493-504.	1.9	111
4	First Clinical Results for PSMA-Targeted α-Therapy Using ²²⁵ Ac-PSMA-I&T in Advanced-mCRPC Patients. Journal of Nuclear Medicine, 2021, 62, 669-674.	5.0	87
5	Evaluation and Management of Postprostatectomy Incontinence: A Systematic Review of Current Literature. European Urology Focus, 2016, 2, 245-259.	3.1	84
6	36â€month data for the AdVance <scp>XP</scp> [®] male sling: results of a prospective multicentre study. BJU International, 2017, 119, 626-630.	2.5	76
7	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. European Urology, 2020, 78, 661-669.	1.9	74
8	Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer after Radical Prostatectomy. Journal of Urology, 2015, 193, 484-490.	0.4	66
9	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. European Urology, 2020, 78, 138-142.	1.9	55
10	Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. European Urology Oncology, 2020, 3, 565-581.	5.4	46
11	Risk factors for artificial urinary sphincter failure. World Journal of Urology, 2016, 34, 595-602.	2.2	45
12	Efficacy and Complications of the Adjustable Sling System ArgusT for Male Incontinence: Results of a Prospective 2-Center Study. Urology, 2015, 85, 316-320.	1.0	44
13	Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients. Oncotarget, 2017, 8, 84180-84192.	1.8	41
14	Surgical Treatment of Male Postprostatectomy Incontinence: Current Concepts. European Urology Focus, 2017, 3, 364-376.	3.1	40
15	Local treatment for metastatic prostate cancer: A systematic review. International Journal of Urology, 2018, 25, 390-403.	1.0	37
16	Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?. World Journal of Urology, 2019, 37, 243-251.	2.2	37
17	Risk Factors for Failure of Male Slings and Artificial Urinary Sphincters: Results from a Large Middle European Cohort Study. Urologia Internationalis, 2017, 99, 14-21.	1.3	34
18	Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage. Scandinavian Journal of Urology, 2017, 51, 130-136.	1.0	33

#	Article	IF	CITATIONS
19	Prognostic features for quality of life after radical cystectomy and orthotopic neobladder. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 1109-1120.	1.5	32
20	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of ⁶⁸ Ga-PSMA and ¹¹ C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. Journal of Urology, 2020, 204, 296-302.	0.4	32
21	Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 529.e11-529.e22.	1.6	31
22	AdVance and AdVance XP slings for the treatment of post-prostatectomy incontinence. World Journal of Urology, 2015, 33, 145-150.	2.2	29
23	Midâ€ŧerm outcomes after AdVanceXP male sling implantation. BJU International, 2016, 118, 458-463.	2.5	28
24	Complications and Short-Term Explantation Rate Following Artificial Urinary Sphincter Implantation: Results from a Large Middle European Multi-Institutional Case Series. Urologia Internationalis, 2016, 97, 205-211.	1.3	27
25	How can we expand active surveillance criteria in patients with low―and intermediateâ€#isk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. BJU International, 2018, 122, 823-830.	2.5	27
26	AdVanceXP male sling: 2-year results of a multicentre study. World Journal of Urology, 2016, 34, 1025-1030.	2.2	26
27	The effect of BMI on clinicopathologic and functional outcomes after open radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 297-302.	1.6	25
28	Long-Term Follow-Up and Oncological Outcome of Patients Undergoing Radical Cystectomy for Bladder Cancer following an Enhanced Recovery after Surgery (ERAS) Protocol: Results of a Large Randomized, Prospective, Single-Center Study. Urologia Internationalis, 2020, 104, 55-61.	1.3	25
29	Efficacy and safety of the ZSI375 artificial urinary sphincter for male stress urinary incontinence: lessons learned. World Journal of Urology, 2016, 34, 1457-1463.	2.2	23
30	Aggressive variants of prostate cancer – Are we ready to apply specific treatment right now?. Cancer Treatment Reviews, 2019, 75, 20-26.	7.7	23
31	Prognostic Features for Objectively Defined Urinary Continence after Radical Cystectomy and Ileal Orthotopic Neobladder in a Contemporary Cohort. Journal of Urology, 2017, 197, 210-215.	0.4	22
32	Validation of a High-End Virtual Reality Simulator for Training Transurethral Resection of Bladder Tumors. Journal of Surgical Education, 2019, 76, 568-577.	2.5	22
33	Surgical High-risk Patients With ASAÂ≥ 3 Undergoing Radical Cystectomy: Morbidity, Mortality, and Predictors for Major Complications in a High-volume Tertiary Center. Clinical Genitourinary Cancer, 2018, 16, e1141-e1149.	1.9	21
34	The AdVance and AdVanceXP male sling in urinary incontinence: is there a difference?. World Journal of Urology, 2018, 36, 1657-1662.	2.2	21
35	Prospective evaluation of health-related quality of life after radical cystectomy: focus on peri- and postoperative complications. World Journal of Urology, 2017, 35, 1223-1231.	2.2	20
36	Male Incontinence: The Etiology or Basis of Treatment. European Urology Focus, 2017, 3, 377-384.	3.1	20

#	Article	IF	CITATIONS
37	Extended followâ€up of the AdVance XP male sling in the treatment of male urinary stress incontinence after 48 months: Results of a prospective and multicenter study. Neurourology and Urodynamics, 2019, 38, 1973-1978.	1.5	20
38	Hereditary prostate cancer – Primetime for genetic testing?. Cancer Treatment Reviews, 2019, 81, 101927.	7.7	20
39	Health-related quality of life after radical cystectomy and ileal orthotopic neobladder: effect of detailed continence outcomes. World Journal of Urology, 2019, 37, 2385-2392.	2.2	20
40	Midterm Health-related Quality of Life After Radical Cystectomy: A Propensity Score–matched Analysis. European Urology Focus, 2020, 6, 704-710.	3.1	20
41	Antibiotic Coating of the Artificial Urinary Sphincter (AMS 800): Is it Worthwhile?. Urology, 2017, 103, 179-184.	1.0	19
42	Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. European Urology Focus, 2021, 7, 742-751.	3.1	19
43	Perioperative patient education improves long-term satisfaction rates of low-risk prostate cancer patients after radical prostatectomy. World Journal of Urology, 2017, 35, 1205-1212.	2.2	18
44	Postoperative upgrading of prostate cancer in men ≥75Âyears: a propensity score-matched analysis. World Journal of Urology, 2017, 35, 1517-1524.	2.2	17
45	A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. European Urology Oncology, 2021, 4, 745-754.	5.4	17
46	Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiation Oncology, 2021, 16, 125.	2.7	17
47	Targeting Moderate and Severe Male Stress Urinary Incontinence With Adjustable Male Slings and the Perineal Artificial Urinary Sphincter: Focus on Perioperative Complications and Device Explantations. International Neurourology Journal, 2017, 21, 109-115.	1.2	17
48	Long-term Outcome of the Retrourethral Transobturator Male Sling After Transurethral Resection of the Prostate. International Neurourology Journal, 2016, 20, 335-341.	1.2	17
49	Surgical learning curve for open radical prostatectomy: Is there an end to the learning curve?. World Journal of Urology, 2015, 33, 1721-1727.	2.2	16
50	Prognostic Value of the Preoperative Platelet-to-leukocyte Ratio for Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer. Clinical Genitourinary Cancer, 2017, 15, e915-e921.	1.9	16
51	Imaging modalities in synchronous oligometastatic prostate cancer. World Journal of Urology, 2019, 37, 2573-2583.	2.2	16
52	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. European Urology, 2020, 78, 779-782.	1.9	16
53	Longâ€ŧerm functional outcome analysis in a large cohort of patients after radical prostatectomy. Neurourology and Urodynamics, 2018, 37, 2263-2270	1.5	15
54	Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS). World Journal of Urology, 2015, 33, 917-922.	2.2	14

#	Article	IF	CITATIONS
55	Open ureteroplasty with buccal mucosa graft for long proximal strictures: A good option for a rare problem. Investigative and Clinical Urology, 2020, 61, 316.	2.0	14
56	Focal Therapy for Prostate Cancer: Complications and Their Treatment. Frontiers in Surgery, 2021, 8, 696242.	1.4	13
57	Artificial Urinary Sphincter Cuff Size Predicts Outcome in Male Patients Treated for Stress Incontinence: Results of a Large Central European Multicenter Cohort Study. International Neurourology Journal, 2019, 23, 219-225.	1.2	13
58	Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1417-1428.	6.4	13
59	Preoperative Thrombocytosis in Patients Undergoing Radical Cystectomy for Urothelial Cancer of the Bladder: An Independent Prognostic Parameter for an Impaired Oncological Outcome. Urologia Internationalis, 2020, 104, 36-41.	1.3	12
60	Bladder Cancer Stage Development, 2004-2014 in Europe Compared With the United States: Analysis of European Population-based Cancer Registries, the United States SEER Database, and a Large Tertiary Institutional Cohort. Clinical Genitourinary Cancer, 2020, 18, 162-170.e4.	1.9	12
61	Impact of Routine Laboratory Parameters in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Long-Term Follow-Up. Urologia Internationalis, 2020, 104, 551-558.	1.3	12
62	Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210819.	3.2	12
63	Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3571-3580.	6.4	12
64	Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy?. World Journal of Urology, 2020, 39, 2537-2543.	2.2	10
65	Five-Year Results of a Prospective Multicenter Trial: AdVance XP for Postprostatectomy-Incontinence in Patients with Favorable Prognostic Factors. Urologia Internationalis, 2021, 105, 421-427.	1.3	10
66	Benefits and Limitations of Transurethral Resection of the Prostate Training With a Novel Virtual Reality Simulator. Simulation in Healthcare, 2020, 15, 14-20.	1.2	9
67	Health-related quality of life after open and robot-assisted radical prostatectomy in low- and intermediate-risk prostate cancer patients: a propensity score-matched analysis. World Journal of Urology, 2020, 38, 3075-3083.	2.2	9
68	High/lowâ€volume center experience predicts outcome of AMS 800 in male stress incontinence: Results of a large middle European multicenter case series. Neurourology and Urodynamics, 2020, 39, 1856-1861.	1.5	9
69	Health-Related Quality of Life following Cytoreductive Radical Prostatectomy in Patients with De-Novo Oligometastatic Prostate Cancer. Cancers, 2021, 13, 5636.	3.7	9
70	Denervation versus pre―and postsynaptic muscle immobilization: Effects On acetylcholine―and muscleâ€specific tyrosine kinase receptors. Muscle and Nerve, 2017, 55, 101-108.	2.2	8
71	Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. Molecular Cancer Therapeutics, 2020, 19, 2210-2220.	4.1	8
72	Is It Safe to Offer Radical Cystectomy to Patients above 85 Years of Age? A Long-Term Follow-Up in a Single-Center Institution. Urologia Internationalis, 2020, 104, 975-981.	1.3	8

Alexander Kretschmer

#	Article	IF	CITATIONS
73	Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate. European Urology Focus, 2020, 7, 1247-1253.	3.1	7
74	Retropubic vs transobturator Argus adjustable male sling: Results from a multicenter study. Neurourology and Urodynamics, 2020, 39, 987-993.	1.5	7
75	PSMA-positive nodal recurrence in prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 637-646.	2.0	7
76	Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 663631.	2.8	7
77	A realâ€world comparison of docetaxel versus abiraterone acetate for metastatic hormoneâ€sensitive prostate cancer. Cancer Medicine, 2021, 10, 6354-6364.	2.8	7
78	Follow-up of high-risk bladder cancer—Is it safe to perform fluorescence endoscopy multiple times in the same patient?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 602.e19-602.e23.	1.6	6
79	The impact of perioperative complications on favorable outcomes after artificial urinary sphincter implantation for post-prostatectomy incontinence. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 632-639.	1.5	6
80	Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence. Current Opinion in Urology, 2022, 32, 69-84.	1.8	6
81	Baseline Health-related Quality of Life Predicts Bladder Cancer–specific Survival Following Radical Cystectomy. European Urology Focus, 2022, 8, 1659-1665.	3.1	6
82	Benefits and Complications during the Stay at an Early Rehabilitation Facility after Radical Cystectomy and Orthotopic Ileum Neobladder Reconstruction. Urologia Internationalis, 2019, 103, 350-356.	1.3	5
83	Fixed or adjustable sling in the treatment of male stress urinary incontinence: results from a large cohort study. Translational Andrology and Urology, 2020, 9, 1099-1107.	1.4	5
84	Routine application of next-generation sequencing testing in uro-oncology—Are we ready for the next step of personalised medicine?. European Journal of Cancer, 2021, 146, 1-10.	2.8	5
85	Salvage cystectomy and ileal conduit urinary diversion as a lastâ€line option for benign diseases—perioperative safety and postoperative healthâ€related quality of life. Neurourology and Urodynamics, 2021, 40, 1154-1164.	1.5	5
86	Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?. Frontiers in Surgery, 2021, 8, 691473.	1.4	5
87	Influence of the laser pulse shape in the treatment of stones in the upper urinary tract. Investigative and Clinical Urology, 2020, 61, 594.	2.0	5
88	Long-term Health-related Quality of Life (HRQOL) After Radical Cystectomy and Urinary Diversion - A Propensity Score-matched Analysis. Clinical Genitourinary Cancer, 2022, 20, e283-e290.	1.9	5
89	Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?. European Urology Focus, 2019, 5, 114-116.	3.1	4
90	Patient Selection in Surgical Centers of Expertise in the Treatment of Patients with Moderate to Severe Male Urinary Stress Incontinence. Urologia Internationalis, 2020, 104, 902-907.	1.3	4

#	Article	IF	CITATIONS
91	Radical Prostatectomy: Sequelae in the Course of Time. Frontiers in Surgery, 2021, 8, 684088.	1.4	4
92	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. European Urology Oncology, 2022, 5, 285-295.	5.4	4
93	Accuracy and prognostic value of radiological lymph node features in variant histologies of bladder cancer. World Journal of Urology, 2022, 40, 1707-1714.	2.2	4
94	Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel—A Real-world Data Assessment. European Urology Focus, 2021, 7, 1308-1315.	3.1	3
95	Impact of previous transurethral prostate surgery on health-related quality of life after radical prostatectomy: Does the interval between surgeries matter?. World Journal of Urology, 2021, 39, 1431-1438.	2.2	3
96	Radical cystectomy for locally advanced urothelial carcinoma of the urinary bladder: Health-related quality of life, oncological outcomes and predictors for survival. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 299.e15-299.e21.	1.6	3
97	Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design. Frontiers in Oncology, 2021, 11, 708595.	2.8	3
98	Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU – YAU Prostate Cancer Working Group multi-institutional study. Central European Journal of Urology, 2021, 74, 362-365.	0.3	3
99	The TiLOOP® Male Sling: Did We Forejudge. Urologia Internationalis, 2018, 100, 216-221.	1.3	2
100	Adherence to guidelines in the management of urolithiasis: are there differences among distinct patient care settings?. World Journal of Urology, 2021, 39, 3079-3087.	2.2	2
101	A matter of size? Healthâ€related quality of life after radical prostatectomy for patients with giant prostates. Prostate, 2021, 81, 443-451.	2.3	2
102	Electromyographic Permutation Entropy Quantifies Diaphragmatic Denervation and Reinnervation. PLoS ONE, 2014, 9, e115754.	2.5	2
103	Molecular Mechanisms Related with Oligometastatic Prostate Cancer—Is It Just a Matter of Numbers?. Cancers, 2022, 14, 766.	3.7	2
104	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer—Current State and Future Perspectives. Cancers, 2022, 14, 147.	3.7	2
105	MP33-10 THE ADVANCEXP MALE SLING: RESULTS OF A PROSPECTIVE MULTICENTER STUDY. Journal of Urology, 2014, 191, .	0.4	1
106	MP88-09 ADVANCE XP MALE SLING: OUTCOME OF A PROSPECTIVE MULTICENTER STUDY. Journal of Urology, 2015, 193, .	0.4	1
107	Secondary Sling Implantation after Failure of Primary Surgical Treatment for Male Stress Urinary Incontinence: A Retrospective Study. Urologia Internationalis, 2020, 104, 625-630.	1.3	1
108	Robotic-assisted Excision of Giant Prostatic Utricular Cysts: Technique, Outcomes and Follow-up. Surgical Technology International, 2019, 35, 43-47.	0.2	1

#	Article	IF	CITATIONS
109	Multicentric comparative analysis of Retzius versus Retzius sparing robotic assisted simple prostatectomy in the management of large prostate glands. Scandinavian Journal of Urology, 2022, 56, 119-125.	1.0	1
110	Health-related quality of life as a prognostic indicator of biochemical recurrence free survival in high-risk prostate cancer patients following radical prostatectomy Journal of Clinical Oncology, 2022, 40, 235-235.	1.6	1
111	Editorial Comment to Treatmentâ€related neuroendocrine prostate cancer resulting in Cushing's syndrome. International Journal of Urology, 2016, 23, 1041-1042.	1.0	0
112	Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 488-497.	1.6	0
113	Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE). European Urology, 2019, 75, 692-693.	1.9	0
114	Re: Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-risk Prostate Cancer with Rising Prostate-specific Antigen Levels After Primary Local Therapy A Randomized Clinical Trial. European Urology, 2019, 76, 405-406.	1.9	0
115	Reply by Authors. Journal of Urology, 2020, 204, 302-302.	0.4	0
116	Editorial Comment. Journal of Urology, 2020, 204, 458-458.	0.4	0
117	Combined Open Prostatectomy and Kidney Surgery: Feasibility and 12-Month Outcome. Research and Reports in Urology, 2021, Volume 13, 815-821.	1.0	0
118	Clinical Implication of Borderline CT-Morphological Metastatic Spread in Bladder Cancer: What You See Is Not Always What You Got. Urologia Internationalis, 2022, , 1-10.	1.3	0
119	The prognostic impact of preoperative health-related quality life on bladder cancer-specific survival in patients treated with radical cystectomy Journal of Clinical Oncology, 2022, 40, 475-475.	1.6	0
120	The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy. Journal of Urology, 0, , .	0.4	0